Peptides for 7-OH and Kratom-Synthetic Withdrawal

What this page is. A neutral, sourced look at peptides being used as adjuncts in recovery contexts: what’s discussed, where readers obtain them, what the evidence supports per peptide, and the safety considerations specific to injectable products from gray-market sources. No peptide is FDA-approved for opioid withdrawal. Some have real (if small and dated) human studies; others are essentially preclinical-only. The community uses them; this page describes the landscape without endorsing any of it.

The first half describes the peptides, doses, routes, access, and cost. The second half covers regulatory status, evidence per peptide, and the safety reality.

The peptides commonly discussed

Peptides are short chains of amino acids that act as signaling molecules in the body. The five most commonly discussed in opioid-withdrawal contexts:

A few others come up in community discussion:

• KPV for GI inflammation (preclinical only)
• GHK-Cu for skin and wound healing (no addiction-relevant evidence)
• Thymalin for immune and aging (Russian preparation; no addiction-relevant clinical evidence)
• Epitalon for sleep and circadian rhythm (very limited evidence)
• Cerebrolysin for cognition (multi-peptide pig-brain hydrolysate; one preclinical morphine-tolerance study, no human RCT in opioid withdrawal)

This page focuses on the five peptides most directly discussed in opioid-withdrawal contexts. The wider peptide landscape exists; this is not a peptide encyclopedia.

For PAWS specifically

PAWS, the months-long stretch of anxiety, sleep disruption, cognitive fog, anhedonia, and stress sensitivity that follows acute withdrawal, is what a lot of this audience is actually using peptides for. The PAWS-relevant peptides map to specific symptoms:

• Selank for the persistent anxiety phenotype. The enkephalin-degradation mechanism (covered below) is mechanistically relevant.
• Semax for cognitive symptoms, brain fog, and attention deficits. Same enkephalin-mechanism family as Selank; documented post-stroke cognitive use in Russia.
• DSIP / Emideltide for sleep disturbance, one of the most persistent PAWS symptoms.
• Epitalon is sometimes discussed for sleep and circadian restoration; evidence is very limited.

No peptide has been studied specifically for PAWS in opioid recovery populations. The PAWS uses are extrapolated from the peptide’s effects in related indications (Selank for general anxiety, Semax for post-stroke cognition, DSIP for sleep). Community practice with theoretical basis, not PAWS-specific clinical evidence. See What is PAWS for the broader symptom picture. BPC-157 and TB-500 sit closer to acute-withdrawal and general-recovery use than the neuropsychiatric symptom profile that defines PAWS.

Doses commonly discussed

Ranges from community sources and, where they exist, from the small human-trial literature. Doses vary widely between practitioners and over time.

These are not protocol recommendations. Doses described in community sources do not carry the dose-response validation that FDA-approved medications go through.

Routes of administration

• Subcutaneous injection (BPC-157, TB-500, sometimes DSIP). Lyophilized powder reconstituted with sterile or bacteriostatic water and injected via insulin syringe. Bacteriostatic water is preferred for multi-use vials since the benzyl alcohol inhibits microbial growth.
• Intranasal (Selank, Semax). Spray or drops absorbed through the nasal mucosa.
• Intravenous (DSIP in the original clinical studies; uncommon outside clinical settings).
• Oral (some BPC-157 formulations; bioavailability is debated since peptides are degraded in the GI tract).

This page is not a how-to-inject guide. Anyone injecting peptides at home is taking on infection and sterility risks that don’t exist with FDA-approved injected medications dispensed through licensed pharmacies.

Supply channels

Categories of access, with no specific clinic, telehealth, or vendor names:

• Compounding pharmacies through licensed prescribers. Highest quality control. FDA actions have progressively restricted what compounding pharmacies can supply (see the regulatory section below).
• Peptide-specialty telehealth clinics. Emerged in recent years; prescribe through compounding pharmacies. Access varies by state.
• Functional and integrative medicine practices. Some prescribe peptides through compounding pharmacies.
• Gray-market “research chemical” suppliers. Sell peptides labeled “for research only.” Legal status complicated; quality control variable to absent. Independent testing has documented systematic purity, identity, and contamination problems (covered in safety below).

The supply-chain-quality difference between these channels is large, and it matters more than it does for FDA-approved medications because there is no regulatory floor below the compounding-pharmacy channel.

Cost

Approximate ranges; insurance does not cover peptide therapy.

The cost gap maps to the supply-chain-quality gap. Cheaper sources carry quality risks that may not show up immediately.

The regulatory landscape, in flux

The FDA’s Pharmacy Compounding Advisory Committee (PCAC) is reviewing several peptides for whether they can be allowed in compounding-pharmacy production. The next scheduled review is July 23 to 24, 2026.

• Day 1: BPC-157, KPV, TB-500, MOTS-C
• Day 2: Emideltide (DSIP), Semax, Epitalon

The PCAC voted against several peptides in late 2024 (CJC-1295, Ipamorelin, AOD-9604, Tα1), which sets a skeptical prior for the July 2026 vote. Outcomes were not yet public at this page’s last update. A second PCAC review (early 2027) is reportedly scheduled for GHK-Cu, Melanotan II, LL-37, Dihexa acetate, and PEG-MGF. Selank is not currently on either calendar.

The trajectory over recent years has been FDA tightening on peptide compounding. Whether the July 2026 review confirms or reverses that trajectory is the open question. Readers should check current status before assuming compounding-pharmacy access is still available for a given peptide.

Evidence per peptide

BPC-157

Preclinical evidence is extensive; clinical evidence is essentially absent. Roughly 100+ rodent studies, mostly from the Sikiric group in Zagreb, document tissue-healing, anti-inflammatory, and gut-protective effects. No published peer-reviewed human RCT exists for any indication as of 2026. A Croatian Phase II for ulcerative colitis (PL-14736) is referenced in review papers but the clinical-trial primary data has never been published. A 2015 U.S. Phase I registration was cancelled in 2016 without data publication. For opioid withdrawal specifically, no human studies of any size exist.

The cancer-promotion concern stemming from BPC-157’s pro-angiogenic mechanism is covered in the safety section below.

Selank

Clinical research is mostly Russian. The mechanistic basis for opioid-context use is documented: Kost et al. 2001 showed that both Selank and Semax inhibit enkephalin-degrading enzymes in human serum (in vitro), meaning these peptides may extend the action of the body’s own endogenous opioid peptides. A 2001 follow-up by the same group reported shortened plasma enkephalin half-life in anxiety patients treated with Selank, linking the in vitro finding to clinical effect.

Anxiolytic effects have been studied in Russian clinical work in general-anxiety populations (vs. benzodiazepine comparators); these studies are mostly published in Russian-language journals and have not been replicated by Western groups. For addiction-population anxiety specifically, only preclinical data (a rat ethanol-withdrawal model) is published.

The mechanism is real; the leap from “inhibits the enzyme in a test tube” to “useful in opioid withdrawal” is mechanistic inference, not demonstrated outcome.

Semax

Same Kost et al. 2001 enkephalin-degradation finding as Selank (Semax slightly more potent in vitro). Russian regulatory approval for post-stroke recovery; on Russia’s List of Vital & Essential Drugs. The post-stroke cognitive evidence base is Russian-published trial work, not replicated internationally at scale. For addiction, Russian work exists in alcohol-withdrawal contexts; no opioid-withdrawal-specific clinical study located.

DSIP / Emideltide

The most directly cited opioid-withdrawal human studies come from one Swiss group in the 1980s. Dick et al. 1983 (Neuropsychobiology) treated 67 inpatients (28 alcohol, 39 opioid) at 25 nmol/kg IV; 49 were evaluable after 27% loss to follow-up. The authors reported beneficial effect in 48 of 49 evaluable patients (26 of 27 opioid cases). A follow-up paper (Dick et al. 1984, European Neurology) extended to 107 inpatients with a similar reported response.

These findings are real but also small, open-label, uncontrolled, no placebo, no randomization, no blinding, single-center, and not independently replicated in the 40+ years since. This is the strongest published clinical evidence for any peptide in opioid withdrawal, and the bar is low.

The trial dose (25 nmol/kg IV, roughly 1,500 to 2,000 mcg for an adult) is dramatically higher than the typical community subcutaneous dose (~100 to 300 mcg before bed). Whether the community dose produces the trial effect is unstudied.

TB-500 (Thymosin Beta-4)

Preclinical evidence for tissue-healing; no human RCT in any indication, let alone opioid withdrawal. The BPC-157 + TB-500 pairing common in recovery protocols is community practice rather than trial-derived. Also on the WADA Prohibited List under S0 (Non-Approved Substances).

The peptides covered briefly above

No peer-reviewed human clinical evidence in opioid withdrawal exists for KPV, GHK-Cu, Thymalin, Epitalon, or Cerebrolysin. Cerebrolysin has one preclinical morphine-tolerance study in rodents and a substantial RCT base in stroke and dementia, but no opioid-withdrawal human work. The others are preclinical or non-addiction-context clinical.

Safety considerations

The risks here are different from other community-discussed adjuncts because the route of administration is injection (for most) and the supply chain often runs through unregulated sources.

Source quality matters more than for FDA-approved medications. Compounding pharmacies dispensing through licensed prescribers carry standard pharmacy quality controls. Gray-market “research chemical” suppliers do not. Independent testing labs that publish their data (Finnrick and Janoshik Analytical are the two most-cited in the community) have documented systematic problems with purity, identity, and contamination across thousands of samples from gray-market suppliers, with substantial fractions failing label-purity claims. Counterfeit and mislabeled products are not edge cases in this market; they are common.

Injection sterility. Reconstituting lyophilized peptide with non-sterile water, reusing needles, contaminating vials, or injecting with poor technique produces real infection risk: cellulitis at the injection site, abscess formation, and bloodstream infection. Bacteriostatic water is preferred for multi-use vials because the benzyl alcohol inhibits microbial growth; sterile water is appropriate for single-use only.

BPC-157 and cancer. BPC-157 promotes VEGFR2-mediated blood vessel formation as part of its healing mechanism, which produces a theoretical concern for promoting growth of undetected or future tumors. A 2025 review in Pharmaceuticals (Jóźwiak et al.) notes that VEGF and its receptors are expressed in about half of human cancers studied; rodent tumor-implantation studies have not shown clear tumor promotion either way. Anyone with cancer history or strong family history should weigh BPC-157 specifically with an oncologist or prescriber rather than starting based on community discussion.

WADA prohibition (BPC-157 and TB-500). Both are on the WADA Prohibited List under S0 (Non-Approved Substances), prohibited at all times in tested sport. Athletes subject to testing cannot use them without violating anti-doping rules. BPC-157 was the first substance ever named explicitly as an example in the S0 category when added in 2022.

Unknown long-term effects. Most peptides discussed here lack the long-term safety data that comes from extended FDA-approved use. Effects over years are not characterized. Pregnancy and breastfeeding are not studied for any of these.

Drug interactions are largely unknown. Anyone on bupe, naltrexone, antidepressants, anticoagulants, or other prescribed medications should treat the lack of interaction data as a reason to ask a prescriber rather than as reassurance.

Options the evidence supports more strongly

For opioid-receptor dependence, including from 7-OH and the kratom synthetics, several paths have substantially stronger evidence than the peptides discussed here:

• Suboxone (buprenorphine), accessible through telehealth providers, with decades of clinical evidence and standard pharmacy-supply quality
• SR-17 is the other medication-assisted path the community has converged on for getting off the synthetics, off-prescription and with thinner clinical literature
• Tapering with kratom leaf and cold turkey with helper medications are the non-MAT options
• For specific PAWS symptoms, evidence-based prescription options include SSRIs for mood, bupropion for motivation, trazodone or doxepin for sleep, and clonidine and gabapentin for acute and post-acute symptoms; see Helper Medications

None of these are exclusive with peptide use. The major medical decision for someone in withdrawal or PAWS rarely turns on “peptides or nothing.”

The decision

The evidence picture varies enormously by peptide. DSIP has the strongest direct opioid-withdrawal evidence and the bar is low (one Swiss group, the 1980s, uncontrolled). Selank and Semax have a real mechanistic basis through the Kost et al. enkephalin-degradation work plus Russian clinical literature in adjacent indications. BPC-157 and TB-500 are essentially preclinical-only in humans. None have been studied specifically for PAWS.

Source quality matters more here than for almost any other category of adjunct on this site, and those risks aren’t theoretical. A reader considering peptides deserves the full picture: what evidence exists for the specific peptide, where it’s sourced, what the safety trade-offs look like, and how the cost compares to the evidence-based alternatives above.

For other adjuncts in this category, see NAD+ IV Therapy and Mega-Dose Vitamin C.

Talking it through

Functional and integrative medicine practitioners and peptide-specialty telehealth clinics are the prescribers who actively engage with peptides. Most standard addiction-medicine prescribers will not have a substantive position; a few have a one-line stance, supportive or skeptical.

For the choice itself, the most useful conversation is usually with someone in the community who has used a specific peptide and can describe the experience, source, cost, and result. The Discord and r/quitting7oh are reasonable starting points. For drug-interaction questions about your prescribed medications, a prescriber is the right address. For BPC-157 with personal or family cancer history, an oncologist’s input is worth having before starting.

Further reading

• NAD+ IV Therapy: the other major investigational adjunct in this space, with similar evidence-gap and cost realities
• Mega-Dose Vitamin C: a much cheaper adjunct with older preliminary literature
• Vitamins & Supplements: supplement-stack background and the broader landscape
• Helper Medications: prescription comfort meds with established evidence
• What is PAWS: the broader symptom picture and other approaches
• Tapering Off 7-OH: community taper patterns
• Telehealth Providers: addiction-medicine telehealth options